Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

December 18, 2007 09:02 ET

Holmes Biopharma, Inc.: Financing and Year End Forecast

SCOTTSDALE, ARIZONA--(Marketwire - Dec. 18, 2007) - Holmes Biopharma, Inc. (OTCBB:HLMB) announces that it has completed a significant working capital financing. The Company can now continue its fantastic growth in sales throughout 2008.

Holmes Biopharma's clinical research subsidiary, Qualia Clinical Services Inc., will finish 2007 with sales of approximately $10 million. Management estimates that sales in 2008 will exceed $20 million, with clinics in Omaha, Nebraska, Toronto, Canada and Kiev, Ukraine operating at full capacity.

Holmes Biopharma's strategy for 2008 includes entering the drug development business with a significant acquisition targeted for early in the new year.

About Holmes:

Holmes Biopharma, Inc. is a contract research organization focused on providing integrated and cost effective clinical development services to the pharmaceutical industry. Currently, clinics operate in Omaha, Nebraska, USA, Toronto, Canada and Kiev, Ukraine. For more information about the company please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors

John F. Metcalfe, President, CEO

Certain statements in this press release constitute "forward looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information